Dexcom Inc (NASDAQ: DXCM) closed the day trading at $133.41 up 0.66% from the previous closing price of $132.53. In other words, the price has increased by $+0.88 from its previous closing price. On the day, 2184854 shares were traded.
Ratios:
For a better understanding of DXCM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 100.47. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Dolan Matthew Vincent sold 4,203 shares for $130.21 per share. The transaction valued at 547,259 led to the insider holds 44,367 shares of the business.
SAYER KEVIN R sold 81,007 shares of DXCM for $10,802,803 on Mar 12 ’24. The President CEO and Chairman now owns 333,526 shares after completing the transaction at $133.36 per share. On Mar 12 ’24, another insider, Stern Sadie, who serves as the EVP Chief Human Resources of the company, sold 20,321 shares for $133.61 each. As a result, the insider received 2,715,006 and left with 80,441 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 51.43B and an Enterprise Value of 51.30B. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 101.79, and their Forward P/E ratio for the next fiscal year is 59.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.20 while its Price-to-Book (P/B) ratio in mrq is 24.86. Its current Enterprise Value per Revenue stands at 14.16 whereas that against EBITDA is 55.96.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $139.55, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is 124.56, while the 200-Day Moving Average is calculated to be 113.94.
Shares Statistics:
Over the past 3-months, DXCM traded about 3.04M shares per day on average, while over the past 10 days, DXCM traded about 2.89M shares per day. A total of 385.40M shares are outstanding, with a floating share count of 377.36M. Insiders hold about 2.12% of the company’s shares, while institutions hold 103.38% stake in the company. Shares short for DXCM as of Feb 29, 2024 were 16.65M with a Short Ratio of 5.48, compared to 18.56M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.32% and a Short% of Float of 4.89%.
Earnings Estimates
Current recommendations for the stock of the company come from 20 analysts. On average, analysts expect EPS of $0.27 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.21, while EPS last year was $0.17. The consensus estimate for the next quarter is $0.39, with high estimates of $0.44 and low estimates of $0.33.
Analysts are recommending an EPS of between $1.88 and $1.57 for the fiscal current year, implying an average EPS of $1.75. EPS for the following year is $2.23, with 21 analysts recommending between $2.51 and $1.99.
Revenue Estimates
20 analysts predict $909.92M in revenue for the current quarter. It ranges from a high estimate of $928M to a low estimate of $877.65M. As of the current estimate, Dexcom Inc’s year-ago sales were $720.74M, an estimated increase of 26.20% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $1.05B, an increase of 24.30% less than the figure of $26.20% in the same quarter last year. There is a high estimate of $1.08B for the next quarter, whereas the lowest estimate is $1.02B.
A total of 24 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.37B, while the lowest revenue estimate was $4.26B, resulting in an average revenue estimate of $4.33B. In the same quarter a year ago, actual revenue was $3.62B, up 19.40% from the average estimate. Based on 24 analysts’ estimates, the company’s revenue will be $5.15B in the next fiscal year. The high estimate is $5.3B and the low estimate is $4.99B. The average revenue growth estimate for next year is up 19.00% from the average revenue estimate for this year.
